2024 AHA热点聚焦：8个最新科学研究，3个最新基础科学研究专场，共69项最新研究结果即将揭晓~

11月16日-18日，2024年美国心脏协会科学年会（2024 AHA）将在在芝加哥以线下+线上结合的方式召开。日前，大会议程已经公布，会议期间共设置8个最新科学研究专场（Late-Breaking Science，共29项最新研究）和3个最新基础科学研究专场（Late Breaking Basic Science, 共40项研究）。在今年的AHA大会上，即将会揭晓哪些重磅研究结果呢？一起先睹为快吧！

最新科学研究

（Late-Breaking Science，LBS）

LBS.01 庆祝心血管科学百年：从预防到治疗，再到治愈

北京时间：11月16日 21:30~22:45

BPROAD - Effects of Intensive Blood Pressure Control in Patients with Type 2 Diabetes (BPROAD)

BPROAD试验：强化血压控制对2型糖尿病患者的影响

SUMMIT - Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
SUMMIT试验：替尔泊肽用于合并肥胖的射血分数保留型心力衰竭患者的治疗Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study
Nexiguran ziclumeran 1期研究中期报告：Nexiguran ziclumeran用于治疗合并转甲状腺素蛋白淀粉样变心肌病（ATTR-CM）患者的疗效和安全性

LBS.02 重新定义心律失常治疗：突破界限

北京时间：11月17日 02:30~03:45

VANISH2 - Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy (VANISH2)

VANISH2试验：缺血性心肌病室性心动过速的导管消融或抗心律失常药物治疗

OPTION - Randomized Comparison of Left Atrial Appendage Closure with Oral Anticoagulation after Catheter Ablation for Atrial Fibrillation (OPTION)
OPTION试验：房颤导管消融术后左心耳封堵 vs 口服抗凝药的随机对照试验

BRAIN AF - Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation (BRAIN AF)
BRAIN AF试验：房颤患者进行抗凝治疗预防缺血性卒中和神经认知障碍的盲法随机试验

LBS.03 智能心脏病学：利用人工智能（AI）和创新改善心脏健康

北京时间：11月17日 04:15~05:30

PHARM-HF A&F - Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study)

PHARM-HF A&F 试验：对退伍军人事务部医疗保健系统中的初级保健药剂师进行随机审核和反馈，以提高心衰用药优化的评估试验

SEISMIC HF-I - Novel AI to Assess Intracardiac Filling Pressure: The Non-invasive SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study
SEISMIC-HF I试验：评估心内充盈压的新型AI技术——无创心震图（SCG）在心衰患者心血管监测中的应用

AI-ECHO - Artificial Intelligence-based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial (Accepted, not confirmed at time of publication)
AI-ECHO随机交叉试验：基于AI的自动超声心动图测量和超声技师的工作流程（已接受，发表时尚未确认）

PanEcho: Complete AI-enabled echocardiography interpretation with multi-task deep learning
PanEcho试验：通过多任务深度学习实现完整的AI超声心动图解读

LBS.04 从干预到预防：冠心病和瓣膜性心脏病研究进展

北京时间：11月17日 21:00~22:15

GLORIOUS - Efficacy of Restrictive versus Liberal Oxygenation in Patients undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial (GLORIOUS)

GLORIOUS随机临床试验：在冠状动脉旁路移植术（CABG）或主动脉瓣置换术（AVR）患者中，比较限制性吸氧与自由性吸氧的疗效

Efficacy of a Glucagon-Like Peptide-1 Agonist in Patients undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial (GLORIOUS)
GLORIOUS随机临床试验：GLP-1受体激动剂在进行CABG或AVR患者中的疗效

ENBALV - Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early after Surgical Bioprosthetic Valve Replacement: ENBALV trial
ENBALV试验：进行外科生物瓣膜置换术的患者在早期应用艾多沙班进行抗凝治疗的有效性和安全性

The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction. The results of the spironolactone factorial.
OASIS 9试验：秋水仙碱 vs. 安慰剂和螺内酯 vs. 安慰剂在心肌梗死患者中的2×2析因随机对照试验

LBS.05 预防创新与全球实施

北京时间：11月18日 04:30~05:45

TOPSPIN - A Three-arm Randomized Trial For Treatment Optimisation Of Blood Pressure With Single-pill Combinations In India

TOPSPIN试验：在印度患者中应用单片复方制剂优化血压控制的三臂随机试验

NUDGE-FLU - Electronic Nudges to Increase Influenza Vaccination among Patients with History of Myocardial Infarction: Insights from 3 Randomized Clinical Trials Enrolling >2 Million Patients (NUDGE-FLU)
NUDGE-FLU试验：电子助推有助于提高既往心肌梗死患者的流感疫苗接种率：来自三项随机临床试验（200多万患者）的见解

ZODIAC - Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies after Acute Coronary Syndrome (ZODIAC)
ZODIAC试验：决策支持系统是否有利于辅助医生优化急性冠脉综合征后早期降脂治疗的实用随机对照试验

MHYH - Preliminary Results of Randomized Trial of New Versus Reconditioned Pacemakers for Patients Unable to Obtain a New Device in Low and Middle-Income Countries: The My Heart Your Heart (MHYH) Randomized Trial
MHYH随机试验：在中低收入国家无法获得新设备的患者中，进行新型起搏器和修复起搏器的随机试验的初步结果

LBS.06 以四大支柱为基础：心力衰竭药物治疗的新试验

北京时间：11月18日 21:00~22:15

ENDEAVOR - Myeloperoxidase Inhibition with Mitiperstat in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Primary Results from the ENDEAVOR Randomized Clinical Trial

ENDEAVOR随机临床试验的主要结果：髓过氧化物酶抑制剂Mitiperstat在治疗射血分数保留和轻度降低的心力衰竭时的疗效

SARAH - Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial – The SARAH Trial
SARAH双盲随机安慰剂对照临床试验：沙库巴曲缬沙坦在接受蒽环类化疗的高危患者中对心脏毒性预防的影响

Novel Bumetanide Nasal Spray (BNS) Demonstrates Safety, Tolerability, and Equivalent Efficacy Compared to Intravenous and Oral Bumetanide (RSQ-777-02)
RSQ-777-02试验：与静脉注射和口服布美他尼相比，新型布美他尼鼻喷雾剂（BNS）安全、耐受性好，且具有同等疗效

REALIZE-K - Sodium Zirconium Cyclosilicate and MRA Optimization in Heart Failure With Reduced Ejection Fraction and Hyperkalemia: Main Results From REALIZE-K Randomized Controlled Trial
REALIZE-K随机对照试验的主要结果：在合并高钾血症的射血分数降低型心力衰竭患者中，进行环硅酸锆钠和MRA优化治疗的疗效

LBS.07 房颤管理的革命性变革：前沿方法

北京时间：11月18日 22:45~24:00

PROMPT-AF - Comparison of Linear Ablation Plus Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone for Persistent Atrial Fibrillation: Results from the PROMPT-AF Randomized Trial

PROMPT-AF随机试验的结果：在持续性房颤患者中，线性消融联合肺静脉隔离 vs单纯肺静脉隔离

CRRF-PeAF - Cryoballoon Ablation versus Radiofrequency Ablation in Patients with Persistent Atrial Fibrillation (CRRF-PeAF): A Prospective, Multicenter, Randomized, Non-inferiority Clinical Trial
CRRF-PeAF前瞻性、多中心、随机、非劣效性临床试验：在持续性房颤患者中，冷冻球囊消融 vs射频消融

TRIM-AF - Randomized Controlled Trial of Metformin and Lifestyle/Risk Factor Modification for Upstream Prevention of Atrial Fibrillation Progression: The Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) Trial
TRIM-AF试验：二甲双胍和改变生活方式/危险因素上游预防房颤进展的随机对照试验

ARREST-AF - Aggressive Risk factor REduction STudy for Atrial Fibrillation (ARREST-AF) implications for ablation outcomes: A Randomized Clinical Trial (Accepted, not confirmed at time of publication)
ARREST-AF随机临床试验：积极进行房颤危险因素管理对消融结果的影响（已接受，发表时尚未确认）

LBS.08 新靶点和新疗法：脂质疗法的进展

北京时间：11月19日 02:30~03:45

ALPACAR - Phase 2 Trial of Zerlasiran: Multiple doses of a Short-Interfering RNA Targeting Lipoprotein(a) over 60 weeks

ALPACAR 2期试验：在60周内多次服用靶向Lp(a)的siRNA药物Zerlasiran的疗效

KRAKEN - A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN)
KRAKEN2期试验：口服干扰Lp(a)颗粒组装的药物Muvalaplin的疗效和安全性

BROOKLYN - Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (BROOKLYN)
BROOKLYN试验：Obicetrapib在治疗杂合子家族性高胆固醇血症患者中的安全性和有效性

最新基础科学研究（部分研究）

（Late Breaking Basic Science, LBBS）

LBBS.AOS.01：探索心脏代谢疾病治疗的新视野：0期之前

北京时间：11月17日 02:30~03:45

Pan-EphB tyrosine kinase inhibitors in obesity and associated metabolic diseases.

Pan-EphB 酪氨酸激酶抑制剂在肥胖和相关代谢疾病中的应用

Combination Therapy with Semaglutide and Inclisiran Reduces Synergisstically Anthracycline-Induced Cardiotoxicity under Hyperlipidemia: New Evidences in Prevention of CTRCD in Cancer Patients

癌症患者预防CTCDC的新证据：Semagulide和Incisiran联合治疗可协同降低高脂血症下蒽环类药物所致的心脏毒性

LBBS.AOS.02：心脏病理生理学的新机制

北京时间：11月17日 21:00~22:15

Dual inhibition of PDE5-mTOR Enhances Chemoimmunotherapeutic Efficacy in Breast Cancer and Reduces Cardiotoxicity

PDE5-mTOR双重抑制可增强乳腺癌化疗患者的疗效，并降低心脏毒性

Novel REV-ERBα/β agonist Ameliorates Heart Failure Induced by Pressure Overload in Mice by Suppressing Aberrant Gene Expression

新型REV-ERBα/β激动剂通过抑制异常基因表达改善小鼠压力超负荷引起的心力衰竭

LBBS.APS.01：心血管健康和疾病的新见解

北京时间：11月17日 23:30~24:15

Chronic administration of the polyamine spermine effectively prolongs the QT interval and prevents life-threatening arrhythmias in a mouse model of Short QT Syndrome Type 3

在3型短QT综合征小鼠模型中，长期服用多胺精胺可有效延长QT间期并预防危及生命的心律失常

Weight Loss Independent Benefits of the GLP-1 Receptor Agonist Semaglutide in Cardiometabolic HFpEF

GLP-1受体激动剂司美格鲁肽在心脏代谢性HFpEF患者中对减肥的独立益处

Nicotinamide Riboside Preserves Systolic Function in a Swine Model of Heart Failure

烟酰胺核苷在猪心力衰竭模型中有助于保留心脏收缩功能

RKER-012, A Novel Modified ActRIIB Ligand Trap, Reversed Experimental Pulmonary Arterial Hypertension (Accepted, not confirmed at time of publication)

KER-012——一种改良的激活素的IIB型受体(ActRIIB) 配体陷阱，可逆转实验性肺动脉高压（已接受，发表时尚未确认）

信源：AHA 2024官网

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。